Summary DT-diaphorase, a homodimeric flavoenzyme, can provide for a defence mechanism against carcinogenesis mediated by dietary or environmental quinones as well as bioactivate quinone-containing chemotherapeutic drugs. Human cell lines and strains have been identified with very low or undetectable enzymatic activity and a C to T transition at nucleotide 609 of the DT-diaphorase cDNA. This single base change is predicted to result in a proline to serine change in amino acid 187. Human cells homozygous for this base transition fail to exhibit Western blot reactivity for DT-diaphorase, suggesting that this substitution results in protein instability. To directly test whether this base change affects DT-diaphorase enzymatic activity and/or protein stability in vivo, mammalian expression vectors containing DT-diaphorase cDNA with or without the nucleotide 609. base transition were transiently transfected in COS-1 cells. Co-transfection with a human growth hormone expression vector allowed normalization for transfection efficiency. COS-1 transfectants expressing the C to T base change displayed at least a tenfold reduction in DT-diaphorase activity (P < 0.001) and a two-to threefold reduction in protein levels compared with wild-type transfectants. These results are the first to detect the presence of DT-diaphorase protein coded for by the 609 base transition in mammalian cells and confirm its predicted reduced enzymatic activity.
In the BE human colon carcinoma cell line, a homozygous C to T base transition in nucleotide 609 of DT-diaphorase cDNA has been implicated in causing low to undetectable DT-diaphorase activity (Traver et al, 1992) . A wide range of DT-diaphorase activities was observed in human fibroblast strains taken from a cancerprone family and unrelated donors (Marshall et al, 1991) . DT-diaphorase activity appeared to be related to the allelic status at nucleotide 609 (C or T) in these cells, also suggesting that this substitution may impair enzyme activity . In addition, the BE cell line and human cell strains that have no or very low DT-diaphorase activity have normal mRNA levels but lack detectable levels of DT-diaphorase protein when tested with polyclonal and/or monoclonal antibodies directed against DT-diaphorase (Marshall et al, 1991; Traver et al, 1997) . To test the hypothesis that this base change impairs DT-diaphorase enzymatic activity, mammalian expression vectors containing DT-diaphorase cDNAs (derived from cells that are homozygous for either the C or T nucleotide at position 609) were transiently transfected into COS-1 monkey kidney cells that express very low levels of endogenous DT-diaphorase activity.
MATERIALS AND METHODS Chemicals and reagents 2,6-Dichlorophenolindophenol (DCPIP), dicoumarol, FAD, bovine serum albumin, and Tris-HCl were obtained from Sigma Chemical (St Louis, MO, USA). Lipofectamine reagent was obtained from Life Technologies (Gibco-BRL, Burlington, ON, Canada) . Recombinant human growth hormone levels in culture medium were determined using a commercially available radioimmunoassay kit (Joldan Diagnostics, Aurora, ON, Canada). Hybridoma supematants containing a mixture of two anti-DT-diaphorase monoclonal antibodies (B771, rat/human NQOI reactive; A180 human NQO1 specific) as well as purified human recombinant DT-diaphorase were supplied by Dr David Ross (University of Colorado Health Sciences Center, Denver, CO, USA).
Preparation of eukaryotic expression vectors Total RNA was isolated from the human fibroblast cell strains GM38 and 3701T, which are homozygous for the C and T nucleotide at position 609 respectively, as previously described . Reverse transcriptase polymerase chain reaction (RT-PCR) was used to amplify cDNAs using Superscript II reverse transcriptase (Gibco) The resulting 895-bp fragments, containing the full-length DTdiaphorase coding region, were inserted into the HindIH and Sail sites of p,3APr-l-neo (Kuehl, 1995) . These constructs were digested with HindlIl and XbaI to release DT-diaphorase cDNAs, which were then gel-purified and subcloned into the pRc/CMV expression vector (Invitrogen, San Diego, CA, USA). Constructs containing DT-diaphorase cDNA inserts with a C or T nucleotide at position 609 were designated as pRc/CMV.DTD609c and pRc/CMV.DTD609T respectively. Constructs were purified for transfection experiments by two rounds of caesium chloride continuous density gradient centrifugation. The sequence integrity of pRc/CMV.DTD609C and pRc/CMV.DTD609T were verified by Sanger sequencing of both strands using Sequence Version 2.0 T7 DNA polymerase (United States Biochemical, Cleveland, OH, USA).
Cell culture COS-1 monkey kidney cells were obtained from the American Type Culture Collection (Rockville, MD, USA) and grown in alpha minimum essential media supplemented with 10% fetal bovine serum (Sigma Chemical, growth medium) and maintained in a humidified atmosphere containing 5% carbon dioxide at 370C.
Transient transfection of NQO1 cDNA COS-1 cells were seeded on 100-mm-diameter tissue culture dishes (NUNC, Denmark) 24 h before transfection at a density of 90-100 cells mm-' in growth medium and maintained in a humidified atmosphere with 5% carbon dioxide at 370C. Lipofectamine transfection was performed according to the manufacturer's protocol (Gibco-BRL). Briefly, transfections were performed using 20 gl (2 mg ml-') lipofectamine and 5 jig of pRc/CMV.DTD609C or pRc/CMV.DTD609T co-transfected with 5 jg of pXGH5 (Seldon et al, 1986 ) in 1.6 ml of antibiotic-free alpha minimal essential media. Mock-transfected cells (Lipofectamine only) and vector-control transfectants (pRc/CMV vector alone) were similarly treated. Cells were incubated with this mixture for 5 h, followed by an overnight incubation with the addition of 10% fetal bovine serum at which time the media were replaced with fresh growth medium. Twenty-four hours later, an aliquot of growth medium was retained for analysis of recombinant human growth hormone levels and cells were harvested for recombinant DT-diaphorase enzymatic assays.
Assay for DT-diaphorase enzymatic activity
Transfectants were harvested by scraping, centrifuged at 250 g for 5 min at 4°C, resuspended in 1 ml of phosphate-buffered saline (PBS), and lysed by exposure to five 10-s ultrasound pulses at 10-s intervals using a Vibra Cell sonicator (Sonics and Materials, Danbury, CT, USA). DT-diaphorase activity, expressed as nmol min-' mg-1 total protein, was determined according to a modification of an assay developed by Benson et al (1980) and is expressed as dicoumarol inhibitable activity measured by the loss of DCPIP at 600 nm. DT-diaphorase activities in cell extracts were determined in the presence of 35 ,UM DCPIP in a buffer containing 25 mM Tris-HCl (pH 7.4), 0.23 mg ml-1 bovine serum albumin, 0.2 mm NADPH, 0.01% Tween-20, 4 gM flavin adenine dinucleotide, with or without 25 tM dicoumarol. Protein concentration was measured using the Bradford method (1976) .
Western blot analysis COS-1 cells were transfected with DT-diaphorase expression vectors, grown to a density of 4 x 105 cells in 100-mm-diameter tissue culture dishes and harvested by scraping in 2 ml of PBS. Half the cell suspension was used to determine DT-diaphorase activity as described above, whereas the remaining half was used for Western blot analysis (Bumette, 1981) . Cell lysates were prepared by resuspending cell pellets in 200 1l-l cell harvest buffer [0.1 M Tris-HCl, 1% sodium dodecyl sulphate (SDS), 10 mM EDTA, 20 nim dithiothreitol (DTT)] and incubation in a boiling water bath for 2 min. Protein concentration was measured using the Bradford method (1976) and protein (20 jg per lane) was separated by 12% SDS polyacrylamide gel electrophoresis and electrotransferred to nitrocellulose membranes. After transfer, membranes were blocked in Tris-buffered saline containing 5% skim milk powder and 1% heat-inactivated fetal bovine serum for 2 h, and then incubated overnight with 15 ml of hybridoma supernatant containing a mixture of two of the anti-DT-diaphorase monoclonal antibodies at 4°C. Blots were washed in Tris-buffered saline containing 0.05% Tween-20 and incubated for 90 min with a 1:4000 dilution of goat anti-mouse horseradish peroxidase conjugated antibody in Tris-buffered saline containing 1% skim milk powder and 1% heat-inactivated fetal bovine serum. Bands were visualized using an enhanced chemiluminesense detection kit (Amersham Life Science, Oakville ON, Canada) and autoradiography. Purified human recombinant DT-diaphorase (20 ng) was included as a positive molecular weight control. Densitometric analysis was performed using a Computing Densitometer and ImageQuant v. 3.3 software package (Molecular Dynamics, Sunnyvale, CA, USA). Band densities were quantified in ng relative to a positive molecular weight control.
Statistical analysis DT-diaphorase activity was expressed as nmol/min/mg protein/ng human growth hormone. Two-way analysis of variance (ANOVA) was used to compare the means of enzymatic activities in COS-l cells transfected with either pRc/CMV.DTD609c or pRc/CMV.DTD609T. Data were evaluated as two treatments (pRc/CMV.DTD6C or pRc/CMV.DTD"T), each was represented by three separate experiments. Two-way ANOVA allows comparison of means of treatments by separating the intraexperimental variation from interexperimental variation.
RESULTS
Co-transfection of COS-1 cells COS-l cells were transiently transfected with eukaryotic expression vectors containing DT-diaphorase cDNAs prepared from mRNA extracted from GM38 or 3701T skin fibroblast strains, which are homozygous for either the C or T nucleotide at position 609 respectively . Untransfected COS-1 cells displayed a background activity within the limit of detection of the assay, as did mock-transfected and vector-control transfected cells (mean ± s.d. of three determinations 3.6 ± 2.2, 3.3 ± 2.2 and 2.0 ± 0.6 nmol min-' mg-' protein respectively). DT-diaphorase activities of pRc/CMV.DTD6wc and pRc/CMV.DTD609T transfectants were corrected for average background enzymatic activity. Two-way ANOVA indicated that DT-diaphorase activities in cells transfected with pRc/CMV.DTD609c or pRc/CMV.DTD609T were significantly different (P <<0.001).
To control for the possibility that differences in DT-diaphorase activities arise from differences in transfection efficiencies, cells were simultaneously transfected with the pXGH5 plasmid, which provides for recombinant human growth hormone expression from the mouse metallothionein-I promotor. Two-way ANOVA indicated that recombinant human growth hormone levels were similar in both pRc/CMV.DTD6wc and pRc/CMV.DTD609T co-transfectants for each experiment (P>>0. 1).
DT-diaphorase activities were normalized to recombinant human growth hormone levels (transfection efficiency) and twoway ANOVA confirmed the significant difference in DTdiaphorase activities in pRc/CMV.DTD609C and pRc/CMV.DTD609T transfectants (P<<0.001) (Figure 1 ). COS-1 cells transfected with pRc/CMV.DTD6wc displayed mean DT-diaphorase activities of 260 ± 110 nmol min-' mg-' protein ng-' hGH, which were tenfold greater than activities observed in pRc/CMV.DTD609T transfectants (25 ± 15 nmol min-m mg-' protein ng-' hGH). These results confirmed that DT-diaphorase cDNAs containing a T nucleotide at position 609 encode a DT-diaphorase protein with reduced enzymatic activity.
Western blot analysis
To examine whether the C to T nucleotide substitution leads to decreased protein stability, recombinant DT-diaphorase protein levels were also examined in COS-1 cells transfected with either the pRc/CMV.DTD609C or pRc/CMV.DTD69T constructs. As shown in Figure 2A , Western blot analysis of two independent pRc/CMV.DTD609C or pRc/CMV.DTD609T transfected cell extracts demonstrated that both mutant and wild-type recombinant DTdiaphorase are expressed at high levels in COS-I cells. The mutant DT-diaphorase protein appeared to run slightly faster than the wild-type DT-diaphorase protein and densitometry ( Figure 2B ) indicated that wild-type transfectants contained approximately threefold greater DT-diaphorase protein than mutant transfectants (mean amounts of DT-diaphorase protein loaded from wild-type and mutant extracts were estimated to be 240 and 80 ng respectively). These results suggest that lower mutant DT-diaphorase enzyme activities cannot be entirely accounted for by a decrease in protein stabilities.
DISCUSSION
DT-diaphorase has been shown to reduce quinone-containing chemotherapeutic drugs such as mitomycin C and the indoloquinone E09 to their hydroquinone forms leading to the formation of DNA-alkylating agents (Verwiej et al, 1994; Workman, 1994) . These drugs may be used to target tumour cells that are rich in DT-diaphorase. Elevated DT-diaphorase activity has been observed in a number of tumour cell lines (Robertson et al, 1992) . Tumour biopsy material from patient lung, colon and breast have also been shown to contain elevated DT-diaphorase activities compared with surrounding normal tissue (Koudstaal et al, 1975; Schlager et al, 1990) . The actual role of DT-diaphorase in controlling cell sensitivity to quinone-containing drugs is, however, controversial as oneelectron reductases may also play important roles, especially in hypoxic cells (Rauth et al, 1993; Rockwell et al, 1993) . The recent work of Fitzsimmons et al (1996) showing a correlation between DT-diaphorase enzymatic activity and aerobic sensitivity to mitomycin C and E09 in the National Cancer Institute human tumour cell line panel is currently the best evidence for this role. The oneelectron reductases NADPH:cytochrome P-450 reductase and NADH:cytochrome b5 reductase fail to display such a correlation in this study. The alternative role for DT-diaphorase as a detoxifying agent, by one-step two-electron reduction of dietary and environmental quinones to redox active products remains a potentially important function for the enzyme (Powis, 1987) .
Cells that are homozygous for a C to T nucleotide transition at position 609 of the DT-diaphorase cDNA were found to contain low to undetectable DT-diaphorase enzymatic activities British Journal of Cancer (1998) 77 (8) (Traver et al, 1992) . It is estimated that approximately 40% of individuals are heterozygous for this nucleotide transition, whereas 10% are homozygous (KuehI et al, 1995) . Limited data have shown that this point mutation is widespread (Rosvold et al, 1995; Rothman et al, 1996) , occurs in both normal tissues and tumours of the same individual (Eickelmann et al, 1994; Traver et al, 1997) and may occur with altered frequencies in different ethnic groups (Rothman et al, 1996) . Observations of human cells that are homozygous for the DTdiaphorase nucleotide 609 point mutation and do not express detectable DT-diaphorase protein (Marshall et al, 1991; Kuehl et al, 1995; Traver et al, 1997) raised the possibility that this mutation leads to destabilization of the protein product. The results in Figure 2 (1995) in studies of an arginine to tryptophan 139 substituted isoform in the HCT 1 16-R30A human colon cancer cell subline, which is resistant to mitomycin C and hooygu frtepIntmtto noigtisfr.Ti mutant DT-diaphorase protein was detected by Western blot analysis in HCT 116-R30A cells, but at 5% of the levels present in the parental mitomycin C-sensitive line. This mutant isoform was also expressed at detectable levels in E. coli and COS-7 cells (Hu et al, 1996) . Therefore, stable expression of this DTdiaphorase isoform may be cell-type specific. However, as the tryptophan 139 mutant has enzymatic activity similar to the wildtype enzyme, the reduced activity displayed by HCT 116-R30A cells has been attributed to the low levels of mutant DTdiaphorase protein. The present paper suggests that the serine 187 mutation results in a reduction in both enzymatic activity and protein stability. Therefore, cells that express the serine 187 mutant would be predicted to be resistant to drugs targeted for DT-diaphorase activation.
The proline to serine substitution at amino acid 187 in DTdiaphorase may predispose individuals to cancer by removing an enzymatic defence mechanism against carcinogenesis. However, the importance of DT-diaphorase in cancer prevention is not clear, and factors such as the interplay of DT-diaphorase with other enzymes acting on common substrates need to be investigated further. The results of this study provide further support for a causal link between the C to T mutation at nucleotide 609 and predisposition to cancer. This mutation may also serve as a prognostic indicator for the effectiveness of chemotherapeutic drugs activated by this enzyme.
